lenalidomide has been researched along with Nausea in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A | 1 |
Bartlett, NL; Blum, KA; Cheson, BD; Johnson, J; Jung, SH; LaCasce, A; Morrison, VA; Pitcher, BN | 1 |
Bekele, NB; Carter, CM; Mathew, P; Pagliaro, L; Tannir, N; Tu, SM | 1 |
Kim, JH; Scialli, AR | 1 |
Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL | 1 |
Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B | 1 |
5 trial(s) available for lenalidomide and Nausea
Article | Year |
---|---|
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Eruptions; Follow-Up Studies; Glycine; Hematologic Diseases; Humans; Lenalidomide; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Nausea; Peripheral Nervous System Diseases; Platelet Count; Thalidomide; Vomiting | 2017 |
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Lymphopenia; Male; Middle Aged; Nausea; Nervous System Diseases; Recurrence; Remission Induction; Thalidomide; Treatment Outcome | 2015 |
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lenalidomide; Male; Middle Aged; Nausea; Neutropenia; Orchiectomy; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Thalidomide; Treatment Outcome; Vomiting | 2010 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid; Male; Middle Aged; Mutation; Nausea; Nuclear Proteins; Nucleophosmin; Prognosis; Remission Induction; Thalidomide; Treatment Outcome; Vomiting | 2013 |
1 other study(ies) available for lenalidomide and Nausea
Article | Year |
---|---|
Thalidomide: the tragedy of birth defects and the effective treatment of disease.
Topics: Abnormalities, Drug-Induced; Angiogenesis Inhibitors; Animals; Dose-Response Relationship, Drug; Ectromelia; Female; Humans; Lenalidomide; Leprosy; Multiple Myeloma; Nausea; Oxidative Stress; Pregnancy; Teratogens; Thalidomide; Treatment Outcome; United States | 2011 |